Sionna Shares Tumble After Cystic-Fibrosis Treatment Unexpectedly Misses Endpoint
Dow Jones
Aug 10
Shares of Sionna Therapeutics tumbled after the company said a midstage, proof-of-concept trial of its treatment for cystic fibrosis didn't meet its key activity endpoint.
The stock lost nearly 90% of its value in premarket trading Monday, falling to $5.27. Shares ended Friday's regular session at $51.04, up 24% year to date.
The biopharmaceutical company said before the bell that potential confounders were observed in the trial, such as higher-than-anticipated levels of variability in individual sweat chloride levels.
"We are disappointed in the unexpected results from the Phase 2a trial," Chief Executive Mike Cloonan said. "We are further evaluating the data to decide on next steps for the SION-451 dual combination."
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.